Skip to main content
SpringerLink
Log in

Aromatase Inhibitor-induced Musculoskeletal Syndrome: a Review of Rehabilitation Interventions

  • Cancer Rehabilitation (SR Smith, Section Editor)
  • Published:
Current Physical Medicine and Rehabilitation Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this narrative review is to highlight clinically relevant characteristics and rehabilitation interventions for aromatase inhibitor-induced musculoskeletal syndrome (AIMSS).

Recent Findings

AIMSS is a constellation of musculoskeletal symptoms including arthralgias, myalgias, and stiffness resulting from estrogen deprivation. The etiology likely relates to estrogen’s role in pain, immune, and skeletal, cartilaginous modulation. Rehabilitation strategies include medications and supplements, resistance, and aerobic exercises. Majority of the rehabilitation studies evaluated exercise interventions.

Summary

AIMSS continues to be a broadly defined condition. The exact pathophysiology has not yet been discovered. Rehabilitation management is multi-dimensional and future research may consider a biopsychosocial approach. While exercise interventions are the most widely studied, there is a need to identify effective exercise protocols. Future research should also evaluate the effectiveness of occupational therapy interventions specifically for AIMSS populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Nyrop KA, Callahan LF, Rini C, Altpeter M, Hackney B, DePue A, et al. Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity. Support Care Cancer. 2016;24:2643–50.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Swenson KK, Nissen MJ, Henly SJ, Maybon L, Pupkes J, Zwicky K, et al. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors. Oncol Nurs Forum. 2013;40:549–57.

    Article  PubMed  Google Scholar 

  3. Institute NC Cancer Stat Facts. https://seer.cancer.gov/statfacts/. Accessed 4/12/2021.

  4. Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

    Article  CAS  Google Scholar 

  5. Bell SG, Dalton L, McNeish BL, Fang F, Henry NL, Kidwell KM, et al. Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients. Gynecol Oncol. 2020;159:509–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Burstein HJ, Lacchetti C, Holly A, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;37:423–38.

    Article  PubMed  Google Scholar 

  7. Paleari L, Rutigliani M, Siri G, Provinciali N, Colombo N, Decensi A. Aromatase inhibitors as adjuvant treatment for ER/PgR positive stage I endometrial carcinoma: a retrospective cohort study. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21062227.

  8. Colon-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Wahner Hendrickson A, et al. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open. 2020;5:e000926. https://doi.org/10.1136/esmoopen-2020-000926.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Shelby RA, Dorfman CS, Bosworth HB, Keefe F, Sutton L, Owen L, et al. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). Contemp Clin Trials. 2019;76:120–31.

    Article  PubMed  Google Scholar 

  10. Tenti S, Correale P, Cheleschi S, Fioravanti A, Pirtoli L. Aromatase inhibitors—induced musculoskeletal disorders: current knowledge on clinical and molecular aspects. Int J Mol Sci. 2020;21:1–38.

    Article  CAS  Google Scholar 

  11. Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, et al. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Res Treat. 2018;169:537–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lintermans A, Van Asten K, Wildiers H, et al. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat. 2014;146:109–16.

    Article  CAS  PubMed  Google Scholar 

  13. Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24:1443–9.

    Article  CAS  PubMed  Google Scholar 

  14. Alhanafy AM, Labeeb A, Khalil A. The role of diuretics in treatment of aromatase inhibitors induced musculoskeletal symptoms in women with non metastatic breast cancer. Asian Pac J Cancer Prev. 2018;19:3525–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111:365–72.

    Article  CAS  PubMed  Google Scholar 

  16. Egawa C, Hirokaga K, Takao S, Yamagami K, Miyashita M, Baba M, et al. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. Int J Clin Oncol. 2016;21:262–9.

    Article  CAS  PubMed  Google Scholar 

  17. Morales L, Pans S, Verschueren K, van Calster B, Paridaens R, Westhovens R, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008;26:3147–52.

    Article  PubMed  Google Scholar 

  18. Xu X, Li X, Liang Y, Ou Y, Huang J, Xiong J, et al. Estrogen modulates cartilage and subchondral bone remodeling in an ovariectomized rat model of postmenopausal osteoarthritis. Med Sci Monit. 2019;25:3146–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Oestergaard S, Sondergaard BC, Hoegh-Andersen P, Henriksen K, Qvist P, Christiansen C, et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum. 2006;54:2441–51.

    Article  CAS  PubMed  Google Scholar 

  20. Garcia-Giralt N, Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-del Pliego E, Balcells S, et al. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat. 2013;140:385–95.

    Article  CAS  PubMed  Google Scholar 

  21. Rodriguez-Sanz M, Garcia-Giralt N, Prieto-Alhambra D, Servitja S, Balcells S, Pecorelli R, et al. CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss. J Mol Endocrinol. 2015;55:69–79.

    Article  CAS  PubMed  Google Scholar 

  22. Servitja S, Martos T, Garrigos L, Rodriguez Sanz M, Garcia Giralt N, Prieto Alhambra D, et al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: Evidence to date and clinical guidance. Ther Adv Med Oncol. 2015;7:291–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bauml J, Chen L, Chen J, Boyer J, Kalos M, Li SQ, et al. Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? Breast Cancer Res. 2015;17:89.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Toesca A, Pagnotta A, Zumbo A, Sadun R. Estrogen and progesterone receptors in carpal tunnel syndrome. Cell Biol Int. 2008;32:75–9.

    Article  CAS  PubMed  Google Scholar 

  25. Beckwee D, Leysen L, Meuwis K, Adriaenssens N. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer. 2017;25:1673–86.

    Article  PubMed  Google Scholar 

  26. Nahm N, Mee S, Marx G. Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review. Asia Pac J Clin Oncol. 2018;14:374–82.

    Article  PubMed  Google Scholar 

  27. Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, et al. Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. Cancer. 2019;125:2123–9.

    Article  CAS  PubMed  Google Scholar 

  28. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30:936–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat. 2010;119:111–8.

    Article  CAS  PubMed  Google Scholar 

  30. Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-García M, Diez-Perez A, et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat. 2011;125:869–78.

    Article  CAS  PubMed  Google Scholar 

  31. Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N, et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat. 2011;129:107–16.

    Article  CAS  PubMed  Google Scholar 

  32. Hershman DL, Unger JM, Greenlee H, et al Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer a randomized clinical trial. In: JAMA - J. Am. Med. Assoc. American Medical Association; 2018 pp 167–176

  33. Bao T, Cai L, Giles JT, Gould J, Tarpinian K, Betts K, et al. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat. 2013;138:167–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer. 2013;21:1077–87.

    Article  PubMed  Google Scholar 

  35. Henry NL, Unger JM, Schott AF, et al Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. In: J. Clin. Oncol. American Society of Clinical Oncology; 2018pp 326–332

  36. Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, et al. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res. 2011;63:821–6.

    Article  Google Scholar 

  37. Paulsen CE, Armache JP, Gao Y, Cheng Y, Julius D. Structure of the TRPA1 ion channel suggests regulatory mechanisms. Nature. 2015;520:511–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Fusi C, Materazzi S, Benemei S, Coppi E, Trevisan G, Marone IM, et al. Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1. Nat Commun. 2014;5:5736. https://doi.org/10.1038/ncomms6736.

    Article  CAS  PubMed  Google Scholar 

  39. Biggs JE, Stemkowski PL, Knaus EE, Chowdhury MA, Ballanyi K, Smith PA. Suppression of network activity in dorsal horn by gabapentin permeation of TRPV1 channels: Implications for drug access to cytoplasmic targets. Neurosci Lett. 2015;584:397–402.

    Article  CAS  PubMed  Google Scholar 

  40. Giorgi S, Nikolaeva-Koleva M, Alarcón-Alarcón D, Butrón L, González-Rodríguez S. Is TRPA1 burning down TRPV1 as druggable target for the treatment of chronic pain? Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20122906.

  41. Khan QJ, Kimler BF, Reddy PS, Sharma P, Klemp JR, Nydegger JL, et al. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. Breast Cancer Res Treat. 2017;166:491–500.

    Article  CAS  PubMed  Google Scholar 

  42. Mcmurdo MET, Sumukadas D, Donnan PT, Cvoro V, Rauchhaus P, Argo I, et al. Spironolactone for people age 70 years and older with osteoarthritic knee pain: a proof-of-concept trial. Arthritis Care Res. 2016;68:716–21.

    Article  CAS  Google Scholar 

  43. Roberts KE, Rickett K, Feng S, Vagenas D, Woodward NE (2020) Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012988.pub2

  44. Lu G, Zheng J, Zhang L. The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors :a systematic review and meta-analysis. Support Care Cancer. 2020;28:1587–96.

    Article  PubMed  Google Scholar 

  45. Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33:1104–11.

    Article  PubMed  Google Scholar 

  46. Patel AV, Friedenreich CM, Moore SC, et al. American College of Sports Medicine Roundtable report on physical activity, sedentary behavior, and cancer prevention and control. Med Sci Sports Exerc. 2019;51:2391–402.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Nyrop KA, Callahan LF, Cleveland RJ, Arbeeva LL, Hackney BS, Muss HB. Randomized controlled trial of a home-based walking program to reduce moderate to severe aromatase inhibitor-associated arthralgia in breast cancer survivors. Oncologist. 2017;22:1238–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Arem H, Sorkin M, Cartmel B, Fiellin M, Capozza S, Harrigan M, et al. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study. J Cancer Surviv. 2016;10:654–62.

    Article  PubMed  PubMed Central  Google Scholar 

  49. van Waart H, van Harten WH, Buffart LM, Sonke GS, Stuiver MM, Aaronson NK. Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer? Psychooncology. 2016;25:964–70.

    Article  PubMed  Google Scholar 

  50. Shaw BA, Spokane LS. Examining the association between education level and physical activity changes during early old age. J Aging Health. 2008;20:767–87.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Bartlett DB, Willis LH, Slentz CA, Hoselton A, Kelly L, Huebner JL, et al. Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study. Arthritis Res Ther. 2018;20:127. https://doi.org/10.1186/s13075-018-1624-x.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Burghardt RD, Kazim MA, Rüther W, Niemeier A, Strahl A. The impact of physical activity on serum levels of inflammatory markers in rheumatoid arthritis: a systematic literature review. Rheumatol Int. 2019;39:793–804.

    Article  CAS  PubMed  Google Scholar 

  53. Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77:1251–60.

    Article  PubMed  Google Scholar 

  54. Roll SC, Hardison ME. Effectiveness of occupational therapy interventions for adults with musculoskeletal conditions of the forearm, wrist, and hand: a systematic review. Am J Occup Ther. 2017;71:7101180010p1–7101180010p12. https://doi.org/10.5014/ajot.2017.023234.

    Article  PubMed  Google Scholar 

  55. Harth A, Germann G, Jester A. Evaluating the effectiveness of a patient-oriented hand rehabilitation programme. J Hand Surg Eur Vol. 2008;33:771–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Physical Medicine and Rehabilitation, University of Utah, 30 North 1900 East, Salt Lake City, UT, 84132, USA

    Sonal Oza

Authors
  1. Sonal Oza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonal Oza.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Conflict of Interest

The author declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Cancer Rehabilitation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oza, S. Aromatase Inhibitor-induced Musculoskeletal Syndrome: a Review of Rehabilitation Interventions. Curr Phys Med Rehabil Rep 9, 119–126 (2021). https://doi.org/10.1007/s40141-021-00318-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40141-021-00318-3

Keywords

Search

Navigation